Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
Multiple claims are unsupported or conflict with the provided metronidazole vaginal gel label excerpts. The label provided supports bacterial vaginosis indication and specific dosing/administration, but does not support trichomoniasis use, alcohol-interaction guidance for vaginal gel, latex/condom diaphragm compatibility statements, symptom-course expectations, or specific adverse-event severity/urgent-care wording as stated.
Category Scores
Accurate Statements
Metronidazole vaginal products are used to treat bacterial vaginosis (BV).
Indications and Usage: Metronidazole vaginal gel indicated for treatment of bacterial vaginosis.
Unsupported Statements
Metronidazole vaginal products are used to treat vaginal infections.
Provided label excerpt specifies bacterial vaginosis; it does not broadly state 'vaginal infections' without specifying BV.
Metronidazole vaginal products are used to treat trichomoniasis in some cases, depending on the specific product and prescribed dose.
Provided label excerpt does not indicate use for trichomoniasis; it instead states other pathogens (including Trichomonas vaginalis) should be ruled out.
Metronidazole comes in vaginal forms including vaginal gel.
The drug in the prompt is metronidazole vaginal gel; however the label excerpts provided do not discuss other vaginal metronidazole forms.
Metronidazole comes in vaginal forms including vaginal cream.
Not supported by the provided label excerpts.
Metronidazole comes in vaginal forms including vaginal tablets/suppositories.
Not supported by the provided label excerpts.
For BV, symptoms often improve within a few days.
No symptom-timeline guidance is provided in the excerpts.
For BV, the full course of metronidazole should be completed even if symptoms improve early.
The label excerpt provides dosing for 5 days but does not provide an explicit instruction about continuing despite early symptom improvement.
People can experience vaginal irritation or discomfort when using metronidazole vaginally.
While 'Vulva/vaginal irritative symptoms' and 'Pelvic discomfort' are listed as adverse events, the statement is more general and does not match the label language specifically; still partially consistent, but not directly supported as phrased.
Burning or itching can occur with metronidazole vaginal treatment.
The label excerpt lists vulva/vaginal irritative symptoms and also notes burning/irritation of the eye; it does not explicitly state 'burning' of vaginal tissue, though generalized itching or rash is mentioned.
Vaginal dryness or discharge changes can occur with metronidazole vaginal treatment.
The label excerpt supports vaginal discharge changes (listed as 'Vaginal discharge') but does not mention vaginal dryness as an adverse reaction.
Mild stomach upset can occur with metronidazole vaginal treatment.
The label excerpt supports 'Gastrointestinal discomfort' and 'Nausea and/or vomiting,' but does not use the phrase 'mild stomach upset.'
Severe pain, swelling, rash, or breathing trouble after metronidazole treatment requires urgent care.
The label excerpt does not provide this urgent-care threshold or list 'breathing trouble' as an adverse reaction; it does discuss neuro/psychotic reactions and hypersensitivity history contraindication.
Metronidazole taken by mouth has a known alcohol interaction.
The label excerpt discusses disulfiram-like reactions with oral metronidazole and alcoholic patients using oral metronidazole with disulfiram concurrently, but it does not state a general 'alcohol interaction' for oral metronidazole as a rule.
The risk of an alcohol interaction with vaginal metronidazole can be lower because less drug is absorbed systemically.
The label excerpt does not provide relative risk statements for vaginal versus oral alcohol interaction.
If using any oral metronidazole or if unsure, it is safer to avoid alcohol during treatment and for a short period after.
The label excerpt does not recommend avoiding alcohol for any defined period; it only addresses disulfiram within the last 2 weeks and possibility of disulfiram-like reaction cannot be excluded.
Metronidazole vaginal formulations can include ingredients that weaken latex, which can be an issue for condom or diaphragm use.
Not supported by the provided label excerpts.
Oil-based metronidazole products are more likely to affect latex.
Not supported by the provided label excerpts.
Metronidazole targets BV and trichomoniasis.
Provided label excerpts only specify BV indication and do not state targeting trichomoniasis.
Metronidazole does not treat yeast infections.
The label excerpt states known or previously unrecognized vaginal candidiasis may present more prominent symptoms during therapy and that symptomatic Candida vaginitis occurred; it does not explicitly say metronidazole does not treat yeast infections.
Contradictions
Low
AI Statement
Metronidazole vaginal products are used to treat trichomoniasis in some cases, depending on the specific product and prescribed dose.
Label Reference
Indications and Usage: Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis, should be ruled out.
Important Omissions
The provided AI claims do not cite the specific FDA-labeled BV dosing regimen (one applicator full ~5 g intravaginally once or twice daily for 5 days; bedtime for once-daily dosing).
Importance:
Moderate
The provided AI claims do not reflect the label’s specific warning points relevant to serious neurologic effects and psychotic reactions (and the caution for central nervous system diseases and disulfiram timing).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims about trichomoniasis treatment and alcohol/latex interactions could lead to misuse relative to the provided label. Some adverse-event statements are not aligned with the label’s wording/thresholds (e.g., urgent care guidance, breathing trouble).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several key claims are unsupported by the provided label excerpts (trichomoniasis use; latex compatibility; specific alcohol-avoidance guidance and rationale; yeast-infection statement).
Suggested Improvement
Restrict claims to what the provided label excerpts support: BV indication; detailed 5-day dosing instructions; label-supported adverse events (e.g., vaginal discharge, vulva/vaginal irritative symptoms, candidiasis risk); and label-specific warnings (neurologic/psychotic reactions and disulfiram timing) without adding unsupported urgent-care or interaction/risk statements.